article thumbnail

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

WCG Clinical

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. In these cases B cell depletion is a feature, not a bug.

In-Vivo 52
article thumbnail

Ginkgo acquires machine learning biotech Patch Biosciences

Drug Discovery World

Ginkgo is also working with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform. Additionally, Ginkgo announced the successful completion of a manufacturing optimisation program with Biogen, focused on redefining the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Q&A with Mark Garner: The golden age of cancer research  

Drug Discovery World

For example, in CAR-T-cell therapy, scientists can take T-cells from a patient and ex vivo (outside the body) genetically engineer them to effectively target and kill cancerous cells, then infuse them back in to the patient. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. Drug discovery and development is an arduous process that can cost upwards of $2.6 In August 2022, the ICH issued an addendum to its S1B guidelines that allows certain drugs to forego two-year rat studies 1.

article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Evolution of such defence mechanisms can lead to multi-drug resistance, further disease progression, and cancer metastasis. Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. This continues to be the standard of care.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

article thumbnail

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

Humanised immune system (HIS) mouse models that express human cytokines and support a broad range of human immune cell types have become integral tools to investigate and advance oncology drug discovery focused on cell-based therapies, which make up a growing proportion of cancer treatments. Jespersen et al.

In-Vivo 52